Приказ основних података о документу
Humoral and Cellular Immune Response after Three Doses of Sinopharm [Vero Cell]-Inactivated COVID-19 Vaccine in Combination with SARS-CoV-2 Infection Leads to Hybrid Immunity
dc.creator | Vukčević, Marija | |
dc.creator | Šerović, Katarina | |
dc.creator | Despot, Mateja | |
dc.creator | Nikolić-Kokić, Aleksandra | |
dc.creator | Vujović, Aleksandra | |
dc.creator | Nikolić, Milan | |
dc.creator | Blagojević, Duško | |
dc.creator | Jovanović, Tanja | |
dc.creator | Despot, Dragana | |
dc.date.accessioned | 2024-01-17T16:24:58Z | |
dc.date.available | 2024-01-17T16:24:58Z | |
dc.date.issued | 2024 | |
dc.identifier.issn | 1424-8247 | |
dc.identifier.uri | http://radar.ibiss.bg.ac.rs/handle/123456789/6495 | |
dc.description.abstract | Background: Several vaccines against COVID-19 have been developed and licensed to enhance the immune response against SARS-CoV-2. Similarly, previous infection with SARS-CoV- 2 has been shown to provide significant protection against severe infection and hospitalization. Methods: We investigated the effect of three doses of the Sinopharm vaccine and SARS-CoV-2 infection on the specific immune response in 103 volunteers, measuring neutralizing antibodies, anti- S1 IgG, anti-RBD IgM, anti-N IgM, anti-N IgG antibodies, and INF γ. Results: Our results showed that the presence of cardiovascular diseases increased the level of anti-N-IgG antibodies, while endocrinological diseases decreased the level of neutralizing antibodies and anti-N IgG antibodies, suggesting that these diseases alter the effect of vaccine-induced immunity. In addition, there was a significant decrease in anti-S1 IgG levels at 6 months and in anti-N IgG levels 18 months post-infection, while neutralizing antibodies and INF γ levels were constant at 3, 6, and 18 months post-infection. Conclusions: Our results confirm the emergence of hybrid immunity, which is the strongest and most durable compared to natural immunity or vaccine-induced immunity. Significant positive correlations were found between humoral and cellular immunity markers: neutralizing antibodies, anti-S1 IgG and anti-N IgG antibodies, and INF γ, indicating a unique coordinated response specific to COVID-19. | sr |
dc.language.iso | en | sr |
dc.publisher | Basel: MDPI | sr |
dc.rights | openAccess | sr |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | Pharmaceuticals | sr |
dc.subject | COVID-19 | sr |
dc.subject | Sinopharm vaccine | sr |
dc.subject | neutralizing antibodies | sr |
dc.subject | anti-S1 IgG antibodies | sr |
dc.subject | anti-RBD IgM antibodies | sr |
dc.subject | anti-N IgM antibodies | sr |
dc.subject | anti-N IgG antibodies | sr |
dc.subject | INF γ | sr |
dc.title | Humoral and Cellular Immune Response after Three Doses of Sinopharm [Vero Cell]-Inactivated COVID-19 Vaccine in Combination with SARS-CoV-2 Infection Leads to Hybrid Immunity | sr |
dc.type | article | sr |
dc.rights.license | BY | sr |
dc.rights.holder | © 2024 by the authors. Licensee MDPI, Basel, Switzerland | sr |
dc.citation.issue | 1 | |
dc.citation.volume | 17 | |
dc.identifier.doi | 10.3390/ph17010122 | |
dc.citation.spage | 122 | |
dc.type.version | publishedVersion | sr |
dc.identifier.fulltext | https://radar.ibiss.bg.ac.rs/bitstream/id/16709/pharmaceuticals-17-00122.pdf | |
dc.citation.rank | M21~ |